Alumis (ALMS) Preferred Stock Liabilities (2023 - 2024)
Alumis (ALMS) posted quarterly Preferred Stock Liabilities of $639.2 million for Q2 2024, up 86.28% year-over-year from $343.2 million in Q3 2023, and up 28.99% quarter-over-quarter from $495.6 million in Q1 2024.
Powered by 
Analysis
Alumis (ALMS) Preferred Stock Liabilities (2023 - 2024) Analysis & Trends
Alumis (ALMS) has reported Preferred Stock Liabilities for 2 consecutive years, with $639.2 million the latest figure, recorded in Q2 2024.
- In Q2 2024, Preferred Stock Liabilities rose 86.28% year-over-year to $639.2 million; the TTM figure through Jun 2024 stood at $639.2 million (up 86.28% YoY), while the FY2023 annual figure was $375.4 million, changed N/A from the prior year.
- Preferred Stock Liabilities advanced to $639.2 million in Q2 2024 per ALMS's latest filing, from $495.6 million in the prior quarter.
- Across five years, Preferred Stock Liabilities topped out at $639.2 million in Q2 2024 and bottomed at $343.2 million in Q2 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Alumis | 1.42 Bn | 919.00 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2024 | 639.24 Mn |
| Mar 31, 2024 | 495.58 Mn |
| Dec 31, 2023 | 375.37 Mn |
| Sep 30, 2023 | 343.15 Mn |
| Jun 30, 2023 | 343.15 Mn |